Read Gene

Read Gene Days Inventory Outstanding

The Days Inventory Outstanding (DIO) of Read Gene (RDG.WA) as of Nov 6, 2026 is 28.00. In the previous year, Days Inventory Outstanding (DIO) was 48.39 — a change of -42.14% (lower).

Days Inventory Outstanding

28.00

YoY

-42.14%

Last updated:

Days Inventory Outstanding (DIO) of Read Gene is 2025 28.00 . Days Inventory Outstanding (DIO) of Read Gene was 2024 48.39 . It decreases by -42.14% lower compared to the previous year.

The Read Gene Days Inventory Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Inventory Outstanding
Date
Days Inventory Outstanding
Jan 1, 2018
2.76 PLN
Jan 1, 2019
2.93 PLN
Jan 1, 2020
0.83 PLN
Jan 1, 2021
13.82 PLN
Jan 1, 2022
10.42 PLN
Jan 1, 2023
46.04 PLN
Jan 1, 2024
48.39 PLN
Jan 1, 2025
28.00 PLN
The Read Gene Days Inventory Outstanding history
YEARDays Inventory OutstandingYoY
28.00-42.14%
48.39+5.11%
46.04+341.98%
10.42-24.61%
13.82+1,565.33%
0.83-71.72%
2.93+6.46%
2.76-28.90%
3.88+12,271.24%
0.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Days Inventory Outstanding (DIO) of Read Gene is 28.00 in 2025.

Days Inventory Outstanding (DIO) of Read Gene changed from 48.39 to 28.00, representing a -42.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Inventory Outstanding (DIO) Read Gene since 2006 – with annual values, charts, and detailed analysis.

DIO measures the average number of days inventory is held before being sold. Lower values indicate more efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Inventory Outstanding (DIO)'s Read Gene with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Inventory Outstanding (DIO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Inventory Outstanding (DIO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Read Gene

All Key Metrics — Read Gene